Corrigendum to Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway (Drug Des Devel Ther. (2015) 9, 4599-4611, 10.2147/DDDT.S85399);Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4599-4611

  Zhou, X ^a   Chen, X ^b   Cai, J J ^b   Chen, L Z ^c   Gong, Y S ^b   Wang, L X ^b   Gao, Z ^a   Zhang, H Q ^a   Huang, W J ^a   Hou, H Z ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU CENTRAL HOSPITAL   (China)

Author keywords

Endothelial to mesenchymal transition; Myocardial fibrosis; Notch; Relaxin; Transforming growth factor

Indexed keywords

CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; JAGGED1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; RELAXIN; TRANSCRIPTION FACTOR HES 1; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; VON WILLEBRAND FACTOR; COLLAGEN; DIPEPTIDE; ISOPRENALINE; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NOTCH1 PROTEIN, HUMAN; NOTCH1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL PARAMETERS; CELL MIGRATION; CELL MOTILITY; CELL TRANSFORMATION; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOTHELIAL MESENCHYMAL TRANSITION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MICROVASCULAR DENSITY; MIGRATION INHIBITION; NONHUMAN; PROTEIN CONTENT; RAT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CARDIOMYOPATHIES; CELL CULTURE; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOMYOPATHIES; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOPROTERENOL; MALE; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS, SPRAGUE-DAWLEY; RECEPTOR, NOTCH1; RELAXIN; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT;

EID: 84939839224     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S130751     Document Type: Erratum

References (43)

1. Zeisberg EM, Kalluri R. Origins of cardiac fibroblasts. Circ Res. 2010;107:1304–1312.
2. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179:1074–1080.
3. Zeisberg EM, Tarnavski O. Endothelial to mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952–961.
4. Widyantoro B, Emoto N, Nakayama K, et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation. 2010;121(22):2407–2418.
5. Kun Ling Ma, Jing Liu, Jie Ni, et al. Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein e knockout mice via endothelial-mesenchymal transition. Int J Med Sci. 2013;10(4):420–426.
6. Hua JY, Zhang ZC, Jiang XH, et al. Relationship between endothelial-to-mesenchymal transition and cardiac fibrosis in acute viral myocarditis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012;41(3):298–304.
7. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther. 2006;112:38–56.
8. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci. 2007;64:1539–1557.
9. Bani D, Yue SK, Bigazzi M. Clinical profile of relaxin, a possible new drug for human use. Curr Drug Saf. 2009;4:238–249.
10. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res. 2009;154:1–6.
11. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145:4125–4133.
12. Bani D, Nistri S, Quattrone S, Bigazzi M, Bani Sacchi T. The vaso relaxant hormone relaxin induces changes in liver sinusoid microcirculation: a morphologic study in the rat. J Endocrinol. 2001;71:541–549.
13. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005;68:96–109.
14. Masterson R, Hewitson TD, Kelynack K, et al. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant. 2004;19:544–552.
15. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739–2745.
16. Teerlink JR, Cotter G, Davison BA, et al; RELAXIN in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
17. Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology. 2010;151:4938–4948.
18. Samuel CS, Cendrawan S, Gao XM, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest. 2011;91:675–690.
19. Pedrazzini T. Control of cardiogenesis by the notch pathway. Trends Cardiovasc Med. 2007;17:83–90.
20. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet. 2008;9:49–61.
21. Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.
22. Grego-Bessa J, Díez J, Timmerman L, et al. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle. 2004;3:718–721.
23. Croquelois A, Domenighetti AA, Nemir M, et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med. 2008;205:3173–3185.
24. Li C, Dong F, Jia Y, et al. Notch signal regulates corneal endothelial-to-mesenchymal transition. Am J Pathol. 2013;183(3):786–795.
25. Loomes KM, Taichman DB, Glover CL, et al. Characterization of Notch receptor expression in the developing mammalian heart and liver. Am J Med Genet. 2002;112:181–189.
26. Chang AC, Fu Y, Garside VC, et al. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev Cell. 2011;21(2):288–300.
27. Elliott GC, Gurtu R, McCollum C, Newman WG, Wang T. Foramen ovale closure is a process of endothelial-to-mesenchymal transition leading to fibrosis. PLoS One. 2014;9(9):e107175.
28. Boccalini G, Sassoli C, Formigli L, Bani D, Nistri S. Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch-1 pathway. FASEB J. 2015;29(1):239–249.
29. Sassoli C, Chellini F, Pini A, et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling. PLoS One. 2013;8(5):e63896.
30. Moore-Morris T, Guimarães-Camboa N, Banerjee I, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest. 2014;124(7):2921–2934.
31. Bani D, Nistri S, Formigli L, Meacci E, Francini F, Zecchi-Orlandini S. Prominent role of relaxin in improving postinfarction heart remodeling. Ann N Y Acad Sci. 2009;1160:269–277.
32. Zhang J, Qi Y-F, Geng B, et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides. 2005;26:1632–1639.
33. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGF beta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci. 2008;121:3317–3324.
34. Li Z, Jimenez SA. Protein kinase C delta and the c-abl kinase are required for transforming growth factor-beta induction of endothelial- mesenchymal transition in vitro. Arthritis Rheum. Epub 2011 Mar 18.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839.
36. Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal. 2013;25:264–268.
37. Samuel CS, Mookerjee I, Halls ML, et al. Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation. Ann N Y Acad Sci. 2009;1160:294–299.
38. Ahmad N, Wang W, Nair R, Kapila S. Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-f pathways. Mol Cell Endocrinol. 2012;363:46–61.
39. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One. 2012;7(8):e42714.
40. Solomon E, Li H, Duhachek Muggy S, Syta E, Zolkiewska A. The role of SnoN in transforming growth factor beta1-induced expression of metallopro- tease-disintegrin ADAM12. J Biol Chem. 2010;285:21969–21977.
41. Nemir M, Metrich M, Plaisance I, et al. The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur Heart J. 2014;35(32):2174–2185.
42. Pan Z, Feng T, Shan L, et al. Scutellarin induced endothelium-independent relaxation in rat aorta. Phytother Res. 2008;22(11):1428–1433. doi: 10.1002/ptr.2364.
43. Luo P, Tan ZH, Zhang ZF, Zhang H, Liu XF, Mo ZJ. Scutellarin isolated from Erigeron multiradiatus inhibits high glucose-mediated vascular inflammation. Yakugaku. 2008;128(9):1293–1299.